Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 45.2 Cr.
- Current Price ₹ 38.6
- High / Low ₹ 159 / 19.6
- Stock P/E 11.2
- Book Value ₹ 25.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 247 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 25.27 | 38.19 | |
| 20.53 | 31.61 | |
| Operating Profit | 4.74 | 6.58 |
| OPM % | 18.76% | 17.23% |
| 1.07 | 0.10 | |
| Interest | 0.65 | 0.51 |
| Depreciation | 0.72 | 0.74 |
| Profit before tax | 4.44 | 5.43 |
| Tax % | 40.77% | 25.41% |
| 2.62 | 4.05 | |
| EPS in Rs | 3.05 | 3.46 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 55% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 11.70 | |
| Reserves | 18.43 | |
| 12.36 | ||
| 16.72 | ||
| Total Liabilities | 59.21 | |
| 10.13 | ||
| CWIP | 2.22 | |
| Investments | 0.00 | |
| 46.86 | ||
| Total Assets | 59.21 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 247.06 | |
| Inventory Days | 127.51 | |
| Days Payable | 199.18 | |
| Cash Conversion Cycle | 175.39 | |
| Working Capital Days | 251.74 | |
| ROCE % |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
30 May 2025 - Earnings call scheduled on June 4, 2025, to discuss FY25 financial results.
-
Updates
30 May 2025 - Appointed EquiBridgeX Advisors as Investor and Public Relations agency from May 30, 2025.
-
Statement of deviation(s) or variation(s) under Reg. 32
29 May 2025 - No deviation in utilization of IPO and preferential issue proceeds for FY 2024-25.
-
Utilisation of Funds
29 May 2025 - Statutory auditor certificate on utilization of issue proceeds submitted as per SEBI norms.
-
Outcome of Board Meeting
29 May 2025 - Approved audited financial results for FY and H1 ended March 31, 2025 with unmodified auditor opinion.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.